Metronidazole

Generic Name: Metronidazole

Brand Names: Flagyl, Flagystatin, Likmez, Metrocream, Metrogel, Metrolotion, Nidagel, Noritate, Nuvessa, Pylera, Rosadan, Vandazole

Drug Type: Small Molecule

Chemical Formula: C_₆H_₉N_₃O_₃

CAS Number: 443-48-1

Unique Ingredient Identifier: 140QMO216E

Advanced Drug Monograph

Access comprehensive pharmacological analysis, clinical applications, and therapeutic considerations.

Background: Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.

Indication: Metronidazole is indicated for the treatment of confirmed trichomoniasis caused by Trichomonas vaginalis (except for in the first trimester of pregnancy) and the patient's sexual partners, bacterial vaginosis, certain types of amebiasis, and various anaerobic infections. The above anaerobic infections may occur on the skin and skin structures, the abdomen, the heart, reproductive organs, central nervous system, and the respiratory system. Some may also be present in the bloodstream in cases of septicemia. Common infections treated by metronidazole are Bacteroides species infections, Clostridium infections, and Fusobacterium infections, as well as Peptococcus and Peptostreptococcus infections. Topical formulations of metronidazole are indicated for the treatment of inflammatory lesions of rosacea.

It is also used off-label in the treatment of Crohn's disease, as a prophylactic agent after surgery, and in the treatment of Helicobacter pylori infection. It has also been studied in the prevention of preterm births and to treat periodontal disease.

Associated Conditions: Abscess Brain, Abscess, Intra-Abdominal, Anaerobic Bacterial Infection, Bacterial Endocarditis, Bacterial Peritonitis, Bacterial Septicemia, Bacterial Vaginosis (BV), Balantidiasis, Bone and Joint Infections, Central Nervous System Bacterial Infections, Empyema, Endometritis, Endomyometritis, Facial Rosacea, Giardiasis, Gynecological Infection, Helicobacter Pylori Infection, Inflammatory Papule, Inflammatory pustules, Liver Abscess, Amebic, Lower respiratory tract infection bacterial, Lung Abscess, Meningitis, Mixed Vaginal Infections, Mixed Vaginal Infections caused by Trichomonas Vaginalis, candida albicans, Periodontitis, Pneumonia, Postoperative Infections, Pouchitis, Skin and skin structure infections, Tetanus, Trichomonas Vaginitis, Tubo-ovarian abscess, Vaginal Candidiasis, Vaginitis Trichomonal, Vulvovaginitis, Acute Intestinal amebiasis, Asymptomatic Trichomoniasis, Entamoeba histolytica, Hepatic abscess, Intra-abdominal bacterial infections, Post-surgical vaginal cuff infection, Refractory Sinusitis, Symptomatic Trichomoniasis

Clinical Trials

Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment

Phase 4

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Esomeprazole
Drug: Bismuth potassium citrate
Drug: Metronidazole
Drug: Clarithromycin
Drug: Levofloxacin
Drug: Amoxicillin
Drug: Tetracycline

First Posted Date: 2022-02-22

Last Posted Date: 2022-03-18

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 388

Registration Number: NCT05250050

Locations: 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, Shanghai, China
🇨🇳
Huashan Hospital, Fudan University, Shanghai, Shanghai, China
🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment

Not Applicable

Completed

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Pariet
Drug: Amolin
Drug: Klaricid
Drug: Flagyl

First Posted Date: 2021-12-09

Last Posted Date: 2022-07-20

Lead Sponsor: Chang Gung Memorial Hospital

Target Recruit Count: 240

Registration Number: NCT05152004

Locations: 🇨🇳
Chang Gung Memorial Hospital, Kaohsiung, Taiwan

Helicobacter Pylori Rescue Treatment in Patients Allergic to Penicillin

Phase 4

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Furazolidone
Drug: Metronidazole

First Posted Date: 2021-11-26

Last Posted Date: 2021-11-30

Lead Sponsor: Shandong University

Target Recruit Count: 170

Registration Number: NCT05135182

Locations: 🇨🇳
Qilu hosipital, Jinan, Shandong, China

Helicobacter Pylori First-line Treatment Containing Tetracycline in Patients Allergic to Penicillin

Phase 4

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Metronidazole
Drug: Levofloxacin

First Posted Date: 2021-11-22

Last Posted Date: 2021-11-24

Lead Sponsor: Shandong University

Target Recruit Count: 106

Registration Number: NCT05129176

Locations: 🇨🇳
Qilu hospital, Jinan, Shandong, China

Comparison Between High-dose Amoxicillin Dual Therapy and Pylera Quadruple Therapy in the Treatment of Helicobacter Pylori Infection

Early Phase 1

Conditions: Gastric Cancer
Helicobacter Pylori Infection
Gastritis

Interventions: Drug: Amoxicillin - high dose dual therapy
Drug: Pylera
Drug: Esomeprazole 40mg

First Posted Date: 2021-10-29

Last Posted Date: 2021-10-29

Lead Sponsor: Hospital da Senhora da Oliveira

Target Recruit Count: 100

Registration Number: NCT05100446

Locations: 🇵🇹
Vítor Bruno Macedo da Silva, Guimarães, Portugal

Helicobacter Pylori Eradication and Follow-up

Phase 4

Recruiting

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Rabeprazole
Drug: Bismuth potassium citrate
Drug: Metronidazole
Drug: Amoxicillin
Drug: Clarithromycin
Drug: Levofloxacin
Drug: Doxycycline
Drug: Tetracycline

First Posted Date: 2021-09-30

Last Posted Date: 2021-09-30

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 4447

Registration Number: NCT05061732

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication

Phase 4

Completed

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Amoxicillin
Drug: Clarithromycin
Drug: Tetracycline
Drug: Metronidazole
Drug: Bismuth Potassium Citrate
Drug: Colloidal Bismuth Pectin
Drug: Vonoprazan fumarate

First Posted Date: 2021-09-20

Last Posted Date: 2023-07-19

Lead Sponsor: Shandong University

Target Recruit Count: 1300

Registration Number: NCT05049902

Locations: 🇨🇳
Maternity and Child Care Health Center of Dezhou, Dezhou, Shandong, China
🇨🇳
Heze Municipal 3rd people's hospital, Heze, Shandong, China
🇨🇳
Qilu hosipital, Jinan, Shandong, China

and more 3 locations